Humoral Response to mRNA Vaccines BNT162b2 and mRNA-1273 COVID-19 in Chronic Lymphocytic Leukemia Patients

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for an ongoing global pandemic. Phase III trials have demonstrated excellent efficacies of mRNA vaccines against SARS-CoV-2 in large population studies (Baden LR, NEJM, 2021; Polack FP, NEJM, 2020). Immunosuppressed individu...

Descripción completa

Detalles Bibliográficos
Autores principales: Bagacean, Cristina, Letestu, Rémi, Al Nawakil, Chadi, Brichler, Ségolène, Lévy, Vincent, Sritharan, Nanthara, Delmer, Alain, Dartigeas, Caroline, Leblond, Véronique, Roos-Weil, Damien, Béné, Marie C, Clavert, Aline, Chaoui, Driss, Genet, Philippe, Guieze, Romain, Laribi, Kamel, Touileb, Yamina, Drenou, Bernard, Willems, Lise, Tomowiak, Cécile, Merabet, Fatiha, Puppink, Christian, Legendre, Hugo, Troussard, Xavier, Malartre, Stéphanie, Cymbalista, Florence, Michallet, Anne-Sophie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology. Published by Elsevier Inc. 2021
Materias:
642.Chronic Lymphocytic Leukemia: Clinical and Epidemiological
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701581/
http://dx.doi.org/10.1182/blood-2021-152515

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701581/
http://dx.doi.org/10.1182/blood-2021-152515

Ejemplares similares